How Much Does Vyleesi (Bremelanotide) Cost in Virginia in 2026?

Virginia Retail Pricing for Brand-Name Vyleesi

The average cash price for brand-name Vyleesi across Virginia retail pharmacies sits at approximately $1,200 per month in 2026, matching the manufacturer list price set by Palatin Technologies. That figure covers a supply of single-dose autoinjectors, each containing 1.75 mg of bremelanotide for subcutaneous self-injection.

Why the Price Stays High

Bremelanotide remains under patent protection with no FDA-approved generic equivalent. Palatin Technologies holds exclusivity, and the drug's niche indication (premenopausal HSDD) limits the competitive pressure that drives prices down in larger therapeutic categories. The FDA-approved prescribing information specifies a maximum of 8 doses per month, so the per-dose cost works out to roughly $150 per injection at list price.

Pharmacy-to-Pharmacy Variation

Prices in Virginia can shift by $50 to $200 depending on the pharmacy chain, location, and whether the pharmacy participates in a group purchasing organization. Independent pharmacies in rural parts of the state sometimes negotiate slightly different wholesale acquisition costs, but the swing rarely drops below $1,000 per month without a discount program or insurance.

Compounded Bremelanotide in Virginia

Licensed 503A compounding pharmacies in Virginia can legally prepare bremelanotide formulations, and this route brings the monthly cost down to roughly $140. That represents an 88% reduction compared to brand-name Vyleesi.

Legal Status of Compounded Bremelanotide in Virginia

Virginia permits 503A compounding under both federal law (the Drug Quality and Security Act of 2013) and state Board of Pharmacy regulations. A 503A pharmacy compounds bremelanotide based on a valid, patient-specific prescription from a licensed prescriber. The compounder must use bulk drug substance from an FDA-registered facility. Virginia does not impose additional state-level restrictions beyond the federal framework for 503A compounding of bremelanotide.

What to Verify Before Choosing a Compounder

Not all compounding pharmacies stock bremelanotide. Patients should confirm three things: the pharmacy holds a current Virginia Board of Pharmacy compounding license, the peptide source is from an FDA-registered supplier, and the pharmacy conducts third-party potency and sterility testing. The FDA's compounding page outlines federal requirements that apply in Virginia.

Dosing Differences

Compounded bremelanotide typically ships as a multi-dose vial with bacteriostatic water for reconstitution, rather than the prefilled autoinjector format of brand Vyleesi. Patients draw up 1.75 mg per dose using an insulin syringe. The injection technique is identical (subcutaneous, abdomen or thigh), but the preparation step adds about 60 seconds.

Virginia Medicaid Coverage for Vyleesi

Virginia Medicaid covers Vyleesi for premenopausal women diagnosed with HSDD, subject to prior authorization (PA). The PA process requires documentation of the diagnosis, confirmation that the patient meets FDA label criteria, and evidence that the condition is not explained by a co-existing medical or psychiatric condition, relationship factors, or medication side effects.

Prior Authorization Requirements

Virginia Medicaid's PA criteria typically include:

• A documented diagnosis of generalized acquired HSDD
• The patient is premenopausal
• The low desire causes marked personal distress (not interpersonal difficulty alone)
• The patient has tried or has a contraindication to flibanserin (Addyi), the oral HSDD treatment
• The prescriber is a physician, NP, or PA with prescriptive authority in Virginia

Approval periods generally run 6 to 12 months before re-authorization. Denials can be appealed through Virginia's Medicaid managed care grievance process.

Processing Timeline

Initial PA decisions in Virginia Medicaid typically take 24 to 72 hours for standard requests. Urgent requests can receive same-day review. The prescriber's office submits the PA electronically through the pharmacy benefit manager (PBM) portal.

Private Insurance Coverage in Virginia

Coverage for Vyleesi varies widely across Virginia's commercial insurance market. Several major carriers operating in Virginia have added Vyleesi to their formularies since the 2019 FDA approval, though almost all require prior authorization and many impose step therapy.

Carriers That Commonly Cover Vyleesi

Anthem Blue Cross Blue Shield (Virginia's largest commercial insurer), Aetna, Cigna, and UnitedHealthcare each have pathways to cover Vyleesi in Virginia. Formulary tier placement ranges from Tier 3 (preferred brand) to non-formulary with exceptions. The RECONNECT phase 3 trials (Kingsberg et al., Obstet Gynecol 2019; N=1,247) provided the clinical evidence base that most insurers reference in their coverage criteria.

Step Therapy

Most Virginia commercial plans require a trial of flibanserin (Addyi) before approving Vyleesi. Flibanserin is an oral, daily medication with different side effects (hypotension, syncope with alcohol). Patients who fail, cannot tolerate, or have contraindications to flibanserin can typically bypass this step. A documented 8-week trial of flibanserin is the most common threshold.

Typical Copays After Approval

With commercial insurance approval, the out-of-pocket cost for Vyleesi in Virginia typically falls between $50 and $150 per month, depending on the plan's specialty tier copay or coinsurance structure. High-deductible health plans (HDHPs) may leave the full cost on the patient until the deductible is met.

Manufacturer Savings and Discount Programs

Palatin Technologies offers a savings card program for commercially insured patients that can reduce the per-month out-of-pocket cost. Eligible patients may pay as little as $50 per month, with the savings card covering the remaining copay or coinsurance up to a maximum annual benefit.

Eligibility Criteria

The savings card is available to patients with commercial insurance. It excludes patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. Virginia residents apply online or through their prescriber's office. The card activates at the pharmacy point of sale.

Other Cost-Reduction Strategies in Virginia

Patients without insurance or with high out-of-pocket costs have several options beyond the manufacturer card:

• Compounded bremelanotide: $140/month from a Virginia-licensed 503A pharmacy, the single largest cost reduction available
• Specialty pharmacy mail order: some Virginia-based specialty pharmacies offer 90-day supplies at a lower per-unit cost than monthly fills
• Patient assistance programs (PAPs): uninsured or underinsured patients may qualify for free medication directly from Palatin Technologies, income thresholds apply
• GoodRx or RxSaver coupons: cash-pay discount cards occasionally bring the retail price below $1,100, though savings are modest compared to compounding

Telehealth Access to Vyleesi in Virginia

Virginia fully permits telehealth prescribing of Vyleesi. A licensed prescriber (MD, DO, NP, or PA) can evaluate a patient via synchronous video visit, diagnose HSDD, and transmit the prescription to a Virginia pharmacy or compounding pharmacy. No in-person visit is required for the initial prescription under current Virginia telehealth law.

How Telehealth Prescribing Works

The prescriber conducts a medical history review, screens for exclusion criteria (uncontrolled hypertension, cardiovascular disease, hepatic impairment), and discusses the FDA-required nausea warning. The Vyleesi label notes that 40% of patients in clinical trials experienced nausea, most commonly within the first few doses. Blood pressure should be measured before prescribing; many telehealth platforms ask patients to provide a recent reading or use a home cuff during the visit.

Virginia Telehealth Regulations

Virginia's telehealth parity law (Va. Code § 38.2-3418.16) requires health insurers to cover telehealth-delivered services at the same rate as in-person visits. This means a telehealth visit for HSDD evaluation and Vyleesi prescribing carries the same copay as an office visit. The DEA's telemedicine prescribing rules do not restrict bremelanotide, as it is not a controlled substance.

Clinical Evidence Supporting Vyleesi

The FDA approved bremelanotide in June 2019 based primarily on the RECONNECT program, two replicate phase 3 randomized controlled trials enrolling 1,247 premenopausal women with HSDD (Kingsberg et al., Obstet Gynecol 2019).

RECONNECT Trial Results

In the RECONNECT trials, bremelanotide 1.75 mg produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo over 24 weeks. The mean increase in SSEs was 1.0 per month above placebo (P<0.001). The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score, measuring personal distress, improved by approximately 0.7 points more than placebo.

Dr. Sheryl Kingsberg, lead investigator on the RECONNECT trials, stated: "Bremelanotide represents a fundamentally different mechanism of action from flibanserin. It works through melanocortin receptors in the central nervous system rather than serotonin pathways, giving clinicians a second pharmacologic option for a condition that affects roughly 1 in 10 premenopausal women."

Safety Profile

The most common adverse event was nausea (40% vs. 1% placebo), which decreased with repeated dosing. Injection site reactions occurred in 13% of patients. Transient increases in blood pressure (systolic increase of 2 to 3 mmHg, diastolic increase of 1 to 2 mmHg) were observed within 12 hours of dosing. Focal skin hyperpigmentation, particularly in darker-skinned patients, occurred in approximately 1% of trial participants. The FDA safety review recommended against use in patients with uncontrolled hypertension or known cardiovascular disease.

How Bremelanotide Compares to Flibanserin

Flibanserin (Addyi) requires daily oral dosing, carries a black-box warning about syncope with alcohol, and is contraindicated with CYP3A4 inhibitors. Bremelanotide is dosed as needed (not daily), has no alcohol interaction, and no CYP-mediated drug interactions of clinical significance. The on-demand dosing model may suit patients who prefer not to take a daily medication. A 2021 network meta-analysis published in the Journal of Sexual Medicine found comparable efficacy between the two drugs for desire-related endpoints, though direct head-to-head trial data remain absent.

Virginia-Specific Considerations

Prescriber Availability

Virginia has a higher-than-average density of OB/GYNs and sexual medicine specialists in the Northern Virginia, Richmond, and Hampton Roads corridors. Rural southwestern Virginia has fewer prescribers familiar with HSDD pharmacotherapy. Telehealth fills much of this gap.

Pharmacy Access

Major chain pharmacies in Virginia (CVS, Walgreens, Kroger) can order Vyleesi, though it may not be stocked routinely due to low dispensing volume. Specialty pharmacies typically carry it or can ship within 1 to 2 business days. For compounded bremelanotide, Virginia-licensed 503A pharmacies are concentrated in the Richmond, Virginia Beach, and Northern Virginia areas, with several offering mail-order statewide.

Insurance Market Structure

Virginia expanded Medicaid in 2019, adding roughly 500,000 adults to the rolls. The six Medicaid managed care organizations (MCOs) operating in Virginia each handle Vyleesi PA through their own pharmacy benefit management systems, so approval timelines and step-therapy requirements can differ slightly by MCO.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges pharmacotherapy as appropriate for HSDD when nonpharmacologic approaches are insufficient (Endocrine Society, JCEM 2019). Virginia-based clinicians referencing this guideline in PA submissions may strengthen their approval rate.

Cost Comparison Summary

| Option | Monthly Cost | Notes | |---|---|---| | Brand Vyleesi, cash pay | ~$1,200 | Retail pharmacy, no discount | | Brand Vyleesi with manufacturer savings card | ~$50 | Commercial insurance required | | Brand Vyleesi with commercial insurance (post-PA) | $50 to $150 | Varies by plan tier | | Brand Vyleesi with Virginia Medicaid | $0 to $8 copay | Prior authorization required | | Compounded bremelanotide (503A) | ~$140 | Virginia-licensed pharmacy; patient-specific Rx |

The widest cost gap in Virginia sits between brand cash-pay ($1,200) and compounded bremelanotide ($140), a difference of $1,060 per month or $12,720 per year.